β‑catenin regulates effects of miR‑24 on the viability and autophagy of glioma cells
Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of miR-24 on the cell viability and autophagy of glioma cells, and how these biological processes are regulated by β-catenin are largely unclea...
Saved in:
Published in | Experimental and therapeutic medicine Vol. 18; no. 2; pp. 1285 - 1290 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Greece
Spandidos Publications UK Ltd
01.08.2019
D.A. Spandidos |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of miR-24 on the cell viability and autophagy of glioma cells, and how these biological processes are regulated by β-catenin are largely unclear. The current study aimed to investigate the role of β-catenin in regulating the effects of miR-24 on the cell viability and autophagy of glioma cells. The expression levels of microtubule-associated proteins 1A/1B light chain 3B (LC3B) and Beclin1 were detected by immunohistochemistry and western blotting. Glioma C6 cells were transfected with miR-24 mimics, miR-24 inhibitors and negative control miRNAs. C6 cells transfected with miR-24 mimics or negative control miRNAs were treated with the β-catenin inhibitor, XAV-939. An MTT assay was utilized to evaluate the viability of C6 cells. The expression of miR-24 and mRNA expression of autophagy related 4a cysteine peptidase (ATG4A) were detected by quantitative polymerase chain reaction analysis. The protein expression of LC3B and Beclin1 decreased significantly in glioma tissue and glioma C6 cells compared with normal brain tissue. Compared with the negative control group, C6 cells transfected with miR-24 mimics exhibited significantly higher cell viability at 24 and 48 h, and those transfected with miR-24 inhibitors exhibited significantly lower cell viability at 48 h. XAV-939 decreased the stimulatory effects of miR-24 mimics on the viability of C6 cells. The expression of miR-24 significantly decreased and ATG4A mRNA significantly increased in C6 cells transfected with XAV-939 compared with those transfected with the negative control miRNA. XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability. In addition, XAV-939 attenuated the miR-24-induced decrease of autophagy marker expression by attenuating miR-24 expression and increasing ATG4A mRNA expression in glioma C6 cells. To the best of our knowledge, the present study is the first to demonstrate whether β-catenin regulates the intracellular effects of miR-24 on the viability and autophagy of glioma cells. The results also provide some mechanistic basis to the pharmaceutical targeting of WNT signaling in high grade glial tumors. |
---|---|
AbstractList | Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of miR-24 on the cell viability and autophagy of glioma cells, and how these biological processes are regulated by β-catenin are largely unclear. The current study aimed to investigate the role of β-catenin in regulating the effects of miR-24 on the cell viability and autophagy of glioma cells. The expression levels of microtubule-associated proteins 1A/1B light chain 3B (LC3B) and Beclin1 were detected by immunohistochemistry and western blotting. Glioma C6 cells were transfected with miR-24 mimics, miR-24 inhibitors and negative control miRNAs. C6 cells transfected with miR-24 mimics or negative control miRNAs were treated with the β-catenin inhibitor, XAV-939. An MTT assay was utilized to evaluate the viability of C6 cells. The expression of miR-24 and mRNA expression of autophagy related 4a cysteine peptidase (ATG4A) were detected by quantitative polymerase chain reaction analysis. The protein expression of LC3B and Beclin1 decreased significantly in glioma tissue and glioma C6 cells compared with normal brain tissue. Compared with the negative control group, C6 cells transfected with miR-24 mimics exhibited significantly higher cell viability at 24 and 48 h, and those transfected with miR-24 inhibitors exhibited significantly lower cell viability at 48 h. XAV-939 decreased the stimulatory effects of miR-24 mimics on the viability of C6 cells. The expression of miR-24 significantly decreased and ATG4A mRNA significantly increased in C6 cells transfected with XAV-939 compared with those transfected with the negative control miRNA. XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability. In addition, XAV-939 attenuated the miR-24-induced decrease of autophagy marker expression by attenuating miR-24 expression and increasing ATG4A mRNA expression in glioma C6 cells. To the best of our knowledge, the present study is the first to demonstrate whether β-catenin regulates the intracellular effects of miR-24 on the viability and autophagy of glioma cells. The results also provide some mechanistic basis to the pharmaceutical targeting of WNT signaling in high grade glial tumors. Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of miR-24 on the cell viability and autophagy of glioma cells, and how these biological processes are regulated by β-catenin are largely unclear. The current study aimed to investigate the role of β-catenin in regulating the effects of miR-24 on the cell viability and autophagy of glioma cells. The expression levels of microtubule-associated proteins 1A/1B light chain 3B (LC3B) and Beclin1 were detected by immunohistochemistry and western blotting. Glioma C6 cells were transfected with miR-24 mimics, miR-24 inhibitors and negative control miRNAs. C6 cells transfected with miR-24 mimics or negative control miRNAs were treated with the β-catenin inhibitor, XAV-939. An MTT assay was utilized to evaluate the viability of C6 cells. The expression of miR-24 and mRNA expression of autophagy related 4a cysteine peptidase (ATG4A) were detected by quantitative polymerase chain reaction analysis. The protein expression of LC3B and Beclin1 decreased significantly in glioma tissue and glioma C6 cells compared with normal brain tissue. Compared with the negative control group, C6 cells transfected with miR-24 mimics exhibited significantly higher cell viability at 24 and 48 h, and those transfected with miR-24 inhibitors exhibited significantly lower cell viability at 48 h. XAV-939 decreased the stimulatory effects of miR-24 mimics on the viability of C6 cells. The expression of miR-24 significantly decreased and ATG4A mRNA significantly increased in C6 cells transfected with XAV-939 compared with those transfected with the negative control miRNA. XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability. In addition, XAV-939 attenuated the miR-24-induced decrease of autophagy marker expression by attenuating miR-24 expression and increasing ATG4A mRNA expression in glioma C6 cells. To the best of our knowledge, the present study is the first to demonstrate whether β-catenin regulates the intracellular effects of miR-24 on the viability and autophagy of glioma cells. The results also provide some mechanistic basis to the pharmaceutical targeting of WNT signaling in high grade glial tumors.Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of miR-24 on the cell viability and autophagy of glioma cells, and how these biological processes are regulated by β-catenin are largely unclear. The current study aimed to investigate the role of β-catenin in regulating the effects of miR-24 on the cell viability and autophagy of glioma cells. The expression levels of microtubule-associated proteins 1A/1B light chain 3B (LC3B) and Beclin1 were detected by immunohistochemistry and western blotting. Glioma C6 cells were transfected with miR-24 mimics, miR-24 inhibitors and negative control miRNAs. C6 cells transfected with miR-24 mimics or negative control miRNAs were treated with the β-catenin inhibitor, XAV-939. An MTT assay was utilized to evaluate the viability of C6 cells. The expression of miR-24 and mRNA expression of autophagy related 4a cysteine peptidase (ATG4A) were detected by quantitative polymerase chain reaction analysis. The protein expression of LC3B and Beclin1 decreased significantly in glioma tissue and glioma C6 cells compared with normal brain tissue. Compared with the negative control group, C6 cells transfected with miR-24 mimics exhibited significantly higher cell viability at 24 and 48 h, and those transfected with miR-24 inhibitors exhibited significantly lower cell viability at 48 h. XAV-939 decreased the stimulatory effects of miR-24 mimics on the viability of C6 cells. The expression of miR-24 significantly decreased and ATG4A mRNA significantly increased in C6 cells transfected with XAV-939 compared with those transfected with the negative control miRNA. XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability. In addition, XAV-939 attenuated the miR-24-induced decrease of autophagy marker expression by attenuating miR-24 expression and increasing ATG4A mRNA expression in glioma C6 cells. To the best of our knowledge, the present study is the first to demonstrate whether β-catenin regulates the intracellular effects of miR-24 on the viability and autophagy of glioma cells. The results also provide some mechanistic basis to the pharmaceutical targeting of WNT signaling in high grade glial tumors. |
Author | Min, Weijie Di, Yunhai Chen, Chao Dai, Dongwei Chen, Hanchun Lu, Qiong Li, Ya'nan Yu, Zhengquan |
AuthorAffiliation | 2 Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China 4 Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China 1 Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu 215021, P.R. China 3 Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China |
AuthorAffiliation_xml | – name: 2 Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – name: 3 Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – name: 4 Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China – name: 1 Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu 215021, P.R. China |
Author_xml | – sequence: 1 givenname: Hanchun surname: Chen fullname: Chen, Hanchun organization: Department of Neurosurgery, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu 215021, P.R. China – sequence: 2 givenname: Qiong surname: Lu fullname: Lu, Qiong organization: Department of Laboratory Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – sequence: 3 givenname: Chao surname: Chen fullname: Chen, Chao organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – sequence: 4 givenname: Yunhai surname: Di fullname: Di, Yunhai organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – sequence: 5 givenname: Ya'nan surname: Li fullname: Li, Ya'nan organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – sequence: 6 givenname: Weijie surname: Min fullname: Min, Weijie organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China – sequence: 7 givenname: Zhengquan surname: Yu fullname: Yu, Zhengquan organization: Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China – sequence: 8 givenname: Dongwei surname: Dai fullname: Dai, Dongwei organization: Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31316620$$D View this record in MEDLINE/PubMed |
BookMark | eNptkc9KHTEUxkNR1FqX3ZaAGzdzzZ9JJtkIIvYPCAVpF12FTCa5NzKTXCcZ4e58BV_FB-lD9Emawau0YhbJgfzOx3fO9x7shBgsAB8xWlAhyanNw4IgLBcNF-gdOMCNJBVGmO1sayQF3gdHKd2gchjHQrA9sE8xxZwTdAB-_X78c_9gdLbBBzja5dSXOkHrnDU5wejg4K8LQmoYA8wrC--8bn3v8wbq0EE95bhe6eVmRpe9j4OGxvZ9-gB2ne6TPdq-h-Dn58sfF1-rq-9fvl2cX1WG1ixX1BJHtJG1dg3lbSctc43gXMpyCWGkqdsWS6RNbZjmpnG6Y22L2qarOUYdPQRnT7rrqR1sZ2zIo-7VevSDHjcqaq_-_wl-pZbxTnGOMKasCJxsBcZ4O9mU1eDTPIIONk5JEcKkRLJmTUGPX6E3cRpDGa9QvDCYcFGoT_86erHyvPUC0CfAjDGl0TplfNbZx9mg7xVGao5XlXjVHK-a4y1d1auuZ-G3-b9q2anP |
CitedBy_id | crossref_primary_10_3389_fonc_2020_597743 crossref_primary_10_3389_fphar_2019_01262 |
Cites_doi | 10.1136/gutjnl-2015-310625 10.18632/oncotarget.2787 10.1083/jcb.201203134 10.1016/j.devcel.2009.06.016 10.1074/jbc.R600027200 10.3892/mmr.2015.4664 10.1371/journal.pone.0001864 10.18632/oncotarget.13550 10.1007/s11060-011-0793-0 10.1016/j.cancergen.2012.10.009 10.18632/oncotarget.11699 10.1038/srep22966 10.1182/blood-2007-05-092718 10.1016/j.febslet.2014.06.017 10.1006/meth.2001.1262 10.1016/j.taap.2013.09.021 10.1083/jcb.201002108 10.1038/nature08356 10.1007/s13277-015-3892-2 10.1158/1535-7163.MCT-15-0857 10.1016/j.canlet.2015.02.003 10.1016/j.molcel.2009.08.020 10.3389/fncel.2017.00318 10.1111/j.1365-2133.2004.06048.x 10.1007/s10753-016-0370-y 10.1002/path.4725 |
ContentType | Journal Article |
Copyright | Copyright Spandidos Publications UK Ltd. 2019 Copyright © 2019, Spandidos Publications 2019 |
Copyright_xml | – notice: Copyright Spandidos Publications UK Ltd. 2019 – notice: Copyright © 2019, Spandidos Publications 2019 |
DBID | AAYXX CITATION NPM 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AN0 BENPR CCPQU FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.3892/etm.2019.7680 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) British Nursing Index with Full Text ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1792-1015 |
EndPage | 1290 |
ExternalDocumentID | PMC6601135 31316620 10_3892_etm_2019_7680 |
Genre | Journal Article |
GeographicLocations | Beijing China United States--US China |
GeographicLocations_xml | – name: China – name: Beijing China – name: United States--US |
GroupedDBID | --- 0R~ 53G 7RV 7X7 8FI 8FJ AAKDD AAYXX ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BENPR BKEYQ BNQBC BPHCQ BVXVI C45 CCPQU CITATION EBD EBS EJD ESX F5P FYUFA H13 HMCUK HUR HZ~ IAO IHR IPNFZ ITC NAPCQ O9- OVD PHGZM PHGZT PQQKQ PROAC RIG RPM TEORI UKHRP 3V. NPM OK1 7XB 8FK K9. PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c345t-3e2f2ac94af736bd9e5f78669986688c9c4bb190ac4c5a6c7fad5bb0b7d4610d3 |
IEDL.DBID | 7X7 |
ISSN | 1792-0981 |
IngestDate | Thu Aug 21 17:47:03 EDT 2025 Fri Jul 11 15:10:49 EDT 2025 Sat Aug 23 13:09:09 EDT 2025 Thu Jan 02 23:04:08 EST 2025 Tue Jul 01 03:33:31 EDT 2025 Thu Apr 24 22:55:17 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 2 |
Keywords | microRNA-24 β-catenin autophagy cell viability glioma C6 cells |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c345t-3e2f2ac94af736bd9e5f78669986688c9c4bb190ac4c5a6c7fad5bb0b7d4610d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Contributed equally |
OpenAccessLink | http://www.spandidos-publications.com/10.3892/etm.2019.7680/download |
PMID | 31316620 |
PQID | 2260941268 |
PQPubID | 2044959 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6601135 proquest_miscellaneous_2259909457 proquest_journals_2260941268 pubmed_primary_31316620 crossref_citationtrail_10_3892_etm_2019_7680 crossref_primary_10_3892_etm_2019_7680 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-08-01 |
PublicationDateYYYYMMDD | 2019-08-01 |
PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Greece |
PublicationPlace_xml | – name: Greece – name: Athens |
PublicationTitle | Experimental and therapeutic medicine |
PublicationTitleAlternate | Exp Ther Med |
PublicationYear | 2019 |
Publisher | Spandidos Publications UK Ltd D.A. Spandidos |
Publisher_xml | – name: Spandidos Publications UK Ltd – name: D.A. Spandidos |
References | Wei (key20200713100450_b9-etm-0-0-7680) 2016; 7 Lal (key20200713100450_b11-etm-0-0-7680) 2008; 3 Wang (key20200713100450_b14-etm-0-0-7680) 2008; 111 Yin (key20200713100450_b15-etm-0-0-7680) 2016; 7 Cui (key20200713100450_b20-etm-0-0-7680) 2016; 239 Bleeker (key20200713100450_b2-etm-0-0-7680) 2012; 108 Singh (key20200713100450_b7-etm-0-0-7680) 2013; 273 Amelio (key20200713100450_b13-etm-0-0-7680) 2012; 199 Saldanha (key20200713100450_b4-etm-0-0-7680) 2004; 151 Pan (key20200713100450_b16-etm-0-0-7680) 2015; 6 MacDonald (key20200713100450_b5-etm-0-0-7680) 2009; 17 Guo (key20200713100450_b23-etm-0-0-7680) 2015; 360 Goodenberger (key20200713100450_b1-etm-0-0-7680) 2012; 205 Lal (key20200713100450_b12-etm-0-0-7680) 2009; 35 Livak (key20200713100450_b19-etm-0-0-7680) 2001; 25 McCord (key20200713100450_b26-etm-0-0-7680) 2017; 11 Liu (key20200713100450_b24-etm-0-0-7680) 2016; 13 Dong (key20200713100450_b8-etm-0-0-7680) 2016; 6 Cherra (key20200713100450_b17-etm-0-0-7680) 2010; 190 Tao (key20200713100450_b6-etm-0-0-7680) 2016; 37 Tian (key20200713100450_b25-etm-0-0-7680) 2016; 39 Chen (key20200713100450_b10-etm-0-0-7680) 2016; 65 Weis (key20200713100450_b3-etm-0-0-7680) 2006; 281 Yan (key20200713100450_b22-etm-0-0-7680) 2014; 588 Huang (key20200713100450_b18-etm-0-0-7680) 2009; 461 Wu (key20200713100450_b21-etm-0-0-7680) 2016; 15 |
References_xml | – volume: 65 start-page: 1522 year: 2016 ident: key20200713100450_b10-etm-0-0-7680 article-title: The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway publication-title: Gut doi: 10.1136/gutjnl-2015-310625 – volume: 6 start-page: 317 year: 2015 ident: key20200713100450_b16-etm-0-0-7680 article-title: Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A publication-title: Oncotarget doi: 10.18632/oncotarget.2787 – volume: 199 start-page: 347 year: 2012 ident: key20200713100450_b13-etm-0-0-7680 article-title: miR-24 triggers epidermal differentiation by controlling actin adhesion and cell migration publication-title: J Cell Biol doi: 10.1083/jcb.201203134 – volume: 17 start-page: 9 year: 2009 ident: key20200713100450_b5-etm-0-0-7680 article-title: Wnt/beta-catenin signaling: Components, mechanisms, and diseases publication-title: Dev Cell doi: 10.1016/j.devcel.2009.06.016 – volume: 281 start-page: 35593 year: 2006 ident: key20200713100450_b3-etm-0-0-7680 article-title: Re-solving the cadherin-catenin-actin conundrum publication-title: J Biol Chem doi: 10.1074/jbc.R600027200 – volume: 13 start-page: 1389 year: 2016 ident: key20200713100450_b24-etm-0-0-7680 article-title: Tissue kallikrein promotes survival and β-catenin degradation in SH-SY5Y cells under nutrient stress conditions via autophagy publication-title: Mol Med Rep doi: 10.3892/mmr.2015.4664 – volume: 3 start-page: e1864 year: 2008 ident: key20200713100450_b11-etm-0-0-7680 article-title: p16(INK4a) translation suppressed by miR-24 publication-title: PLoS One doi: 10.1371/journal.pone.0001864 – volume: 7 start-page: 86755 year: 2016 ident: key20200713100450_b15-etm-0-0-7680 article-title: TRIM11, a direct target of miR-24-3p, promotes cell proliferation and inhibits apoptosis in colon cancer publication-title: Oncotarget doi: 10.18632/oncotarget.13550 – volume: 108 start-page: 11 year: 2012 ident: key20200713100450_b2-etm-0-0-7680 article-title: Recent advances in the molecular understanding of glioblastoma publication-title: J Neurooncol doi: 10.1007/s11060-011-0793-0 – volume: 205 start-page: 613 year: 2012 ident: key20200713100450_b1-etm-0-0-7680 article-title: Genetics of adult glioma publication-title: Cancer Genet doi: 10.1016/j.cancergen.2012.10.009 – volume: 7 start-page: 65374 year: 2016 ident: key20200713100450_b9-etm-0-0-7680 article-title: ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway publication-title: Oncotarget doi: 10.18632/oncotarget.11699 – volume: 6 start-page: 22966 year: 2016 ident: key20200713100450_b8-etm-0-0-7680 article-title: The Wnt/β-catenin signaling/Id2 cascade mediates the effects of hypoxia on the hierarchy of colorectal-cancer stem cells publication-title: Sci Rep doi: 10.1038/srep22966 – volume: 111 start-page: 588 year: 2008 ident: key20200713100450_b14-etm-0-0-7680 article-title: MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4 publication-title: Blood doi: 10.1182/blood-2007-05-092718 – volume: 588 start-page: 3038 year: 2014 ident: key20200713100450_b22-etm-0-0-7680 article-title: miR-96/HBP1/Wnt/β-catenin regulatory circuitry promotes glioma growth publication-title: FEBS Lett doi: 10.1016/j.febslet.2014.06.017 – volume: 25 start-page: 402 year: 2001 ident: key20200713100450_b19-etm-0-0-7680 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method publication-title: Methods doi: 10.1006/meth.2001.1262 – volume: 273 start-page: 418 year: 2013 ident: key20200713100450_b7-etm-0-0-7680 article-title: Green tea polyphenol, (−)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting β-catenin signaling publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2013.09.021 – volume: 190 start-page: 533 year: 2010 ident: key20200713100450_b17-etm-0-0-7680 article-title: Regulation of the autophagy protein LC3 by phosphorylation publication-title: J Cell Biol doi: 10.1083/jcb.201002108 – volume: 461 start-page: 614 year: 2009 ident: key20200713100450_b18-etm-0-0-7680 article-title: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling publication-title: Nature doi: 10.1038/nature08356 – volume: 37 start-page: 1097 year: 2016 ident: key20200713100450_b6-etm-0-0-7680 article-title: MSX1 inhibits cell migration and invasion through regulating the Wnt/β-catenin pathway in glioblastoma publication-title: Tumour Biol doi: 10.1007/s13277-015-3892-2 – volume: 15 start-page: 1656 year: 2016 ident: key20200713100450_b21-etm-0-0-7680 article-title: MSK1-mediated β-catenin phosphorylation confers resistance to PI3K/mTOR inhibitors in glioblastoma publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-15-0857 – volume: 360 start-page: 76 year: 2015 ident: key20200713100450_b23-etm-0-0-7680 article-title: miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1 publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.02.003 – volume: 35 start-page: 610 year: 2009 ident: key20200713100450_b12-etm-0-0-7680 article-title: miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to ‘seedless’ 3′UTR microRNA recognition elements publication-title: Mol Cell doi: 10.1016/j.molcel.2009.08.020 – volume: 11 start-page: 318 year: 2017 ident: key20200713100450_b26-etm-0-0-7680 article-title: Targeting WNT signaling for multifaceted glioblastoma therapy publication-title: Front Cell Neurosci doi: 10.3389/fncel.2017.00318 – volume: 151 start-page: 157 year: 2004 ident: key20200713100450_b4-etm-0-0-7680 article-title: Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2004.06048.x – volume: 39 start-page: 1387 year: 2016 ident: key20200713100450_b25-etm-0-0-7680 article-title: PGRN suppresses inflammation and promotes autophagy in keratinocytes through the Wnt/β-catenin signaling pathway publication-title: Inflammation doi: 10.1007/s10753-016-0370-y – volume: 239 start-page: 297 year: 2016 ident: key20200713100450_b20-etm-0-0-7680 article-title: Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling publication-title: J Pathol doi: 10.1002/path.4725 |
SSID | ssj0000561885 |
Score | 2.1881032 |
Snippet | Mutations of the β-catenin gene are common in various cancer types. MicroRNA (miR)-24 suppresses gene expression during the cell cycle. However, the effects of... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1285 |
SubjectTerms | Antibiotics Apoptosis Autophagy Binding sites Biotechnology Brain cancer Cell adhesion & migration Cell cycle Cell growth Colorectal cancer Glioma Kinases Laboratory animals Liver cancer Lung cancer Medical prognosis Mutation Prostate cancer Protein expression Proteins Skin cancer Tumors |
Title | β‑catenin regulates effects of miR‑24 on the viability and autophagy of glioma cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31316620 https://www.proquest.com/docview/2260941268 https://www.proquest.com/docview/2259909457 https://pubmed.ncbi.nlm.nih.gov/PMC6601135 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELYoXHqp2tLHtoCMhPa0LhvbsZNTVSoQQgKtECvtLbIdh0YCB8hupf1b_SH9TZ1Jstluq_bsUV7feF4Zf0PIEUAMblgJVhRgAqUaW2as1iyysY0EuDjfTG-4vFLnU3kxi2ddwa3u2ipXNrEx1HnlsEZ-DGECZCIRV8nnh0eGU6Pw72o3QuMZ2UHqMtRqPdN9jQWj46SZyglqx9k4TaKWZhO8ND_2czyJHqWfIOIeb7qlv2LNP1smf_NBZy_Jiy54pF9atF-RLR9ek-GkZZ9ejujN-jBVPaJDOlnzUi93yfTnD4b9T6EM9KkdQe9r2jV00Kqg9-U145JWgUJUSL-XLYX3kpqQU7NABgJzu0TB27uyujcUi_71GzI9O735es66qQrMCRnPmfC84Mal0hRaKJunPi50ohTkXUoliUudtBbCBOOki41yujB5bO3Y6hy52XPxlmyHKvj3hGJuaLjhAiSkSVIL5sF6keQqlyaVbkBGq4-auY5yHCdf3GWQeiAGGWCQIQYZYjAgw178oeXa-Jfg3gqhrNtydbZWkAE57Jdhs-DHMMFXC5SJwfuCeuoBedcC2t9JRCJSisPF9QbUvQAScW-uhPJbQ8itIKuNRPzh_4_1kTzHN2i7B_fI9vxp4fchopnbg0ZtD8jOyenV5PoX8m73xQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAF8WZpASPBntY0sR0nOSCEgGpLH6rQrrS3YDtOidQmbbMLyp_iwA_hNzGzeSwLglvPGTmJvxnPjD3-hpAXADG4YSVYlsESKJVnmDZhyHwTGF-Ai3PL7g2HR2o8lR9nwWyDfO_uwmBZZbcmLhfqtLS4R74DYQJkIj5X0ZvzC4Zdo_B0tWuh0ajFvqu_QcpWvd57D_i-5Hz3w-TdmLVdBZgVMpgz4XjGtY2lzkKhTBq7IAsjpSDvUCqKbGylMeAmtZU20MqGmU4DYzwTpshNngoY9xq5Do7Xw2QvnIX9ng5G49GyCyioOWdeHPkNrSdEBXzHzfHmux-_ggjfW3eDf8W2f5Zo_ubzdm-TW22wSt822nWHbLjiLhkeN2zX9YhOVpe3qhEd0uMVD3Z9j0x__mBYb1XkBb1sWt67irYFJLTM6Fn-iXFJy4JCFEq_5g1leE11kVK9QMYDfVKj4MlpXp5piocM1X0yvZL5fkA2i7JwjwjFXFRzzQVISB3FBpYj40SUqlTqWNoBGXWTmtiW4hw7bZwmkOogBglgkCAGCWIwIMNe_Lzh9viX4HaHUNKaeJWsFHJAnvePwThxMnThygXKBODtwRzCAXnYANq_SfjCV4rD4OEa1L0AEn-vPynyL0sCcAVZtC-Cx___rGfkxnhyeJAc7B3tb5Gb-DdN5eI22ZxfLtwTiKbm5ulShSn5fNU28wswrjQn |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJyFeEP8pDDAS9Kmmje04yQNCwFZtDKpqWqW9ZbbjlEhbMpYWlK_FIx-Cz8Rdk7QUBG97zslJ_Lvz3dnn3xHyAiAGN6wES1NYAqUaGqZNEDDP-MYT4OLcsnvDp7Han8oPJ_7JFvnR3oXBssp2TVwu1ElhcY98AGECZCIeV-EgbcoiJrujNxdfGHaQwpPWtp1GrSKHrvoG6Vv5-mAXsH7J-Wjv-P0-azoMMCukP2fC8ZRrG0mdBkKZJHJ-GoRKQQ6iVBjayEpjwGVqK62vlQ1SnfjGDE2QIE95ImDca2Q7wKyoQ7bf7Y0nR6sdHozNw2VPUFB6zoZR6NUknxAj8IGb4z14L3oF8f5w0yn-Fen-WbD5mwcc3SI3m9CVvq117TbZcvkd0pvU3NdVnx6vr3KVfdqjkzUrdnWXTH9-Z1h9lWc5vXQz7BrmStqUk9AipefZEeOSFjmFmJR-zWoC8YrqPKF6gfwHelah4OwsK841xSOH8h6ZXsmM3yedvMjdQ0IxM9VccwESUoeRgcXJOBEmKpE6krZL-u2kxrYhPMe-G2cxJD6IQQwYxIhBjBh0SW8lflEzffxLcKdFKG4MvozX6tklz1ePwVRxMnTuigXK-OD7wTiCLnlQA7p6k_CEpxSHwYMNqFcCSAO--STPPi_pwBXk1J7wH_3_s56R62Av8ceD8eFjcgN_pi5j3CGd-eXCPYHQam6eNjpMyelVm80vjdg5wg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2%E2%80%91catenin+regulates+effects+of+miR%E2%80%9124+on+the+viability+and+autophagy+of+glioma+cells&rft.jtitle=Experimental+and+therapeutic+medicine&rft.au=Chen%2C+Hanchun&rft.au=Lu%2C+Qiong&rft.au=Chen%2C+Chao&rft.au=Di%2C+Yunhai&rft.date=2019-08-01&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892%2Fetm.2019.7680&rft.externalDBID=n%2Fa&rft.externalDocID=10_3892_etm_2019_7680 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1792-0981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1792-0981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1792-0981&client=summon |